Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Association of Obesity based on Different Metabolic Status with Risk of Gout Occurrence in Patients: A National Study

Author(s): Yanyan Wang, Luna Liu, Shizhan Ma, Junming Han, Zhixiang Wang, Xiude Fan* and Xu Hou*

Volume 24, Issue 8, 2024

Published on: 02 October, 2023

Page: [973 - 980] Pages: 8

DOI: 10.2174/1871530323666230911140635

Price: $65

Abstract

Background: Obesity often co-exists with metabolic abnormalities, but the results of studies on the relationship between obesity, metabolic abnormalities and the risk of gout are inconsistent.

Objectives: We aimed to study whether there was a mutual regulation between obesity, metabolic abnormalities and the risk of gout.

Methods: We conducted a cross-sectional study to expound the association between obesity based on different metabolic statuses and the risk of gout. Patients were derived from Nationwide Readmission Database (2018 sample).

Results: A total of 9,668,330 records were recruited for analysis from January to December. The risk of gout in the obesity group, metabolic abnormalities group and obesity combined with metabolic abnormalities group was 1.67 times (OR = 1.67, 95%CI 1.64-1.70), 3.12 times (OR = 3.12, 95%CI 3.09-3.15) and 4.27 times (OR = 4.27, 95%CI 4.22-4.32) higher than that in the normal control group. For different metabolic components, OR value was highest in hypertension group (OR = 2.65, 95%CI 2.60-2.70 and OR = 4.85, 95%CI 4.73-4.97), followed by dyslipidemia group (OR = 2.23, 95%CI 2.16-2.30 and OR = 3.74, 95%CI 3.55-3.95) and in hyperglycemia group (OR = 1.73, 95%CI 1.66-1.80 and OR = 2.94, 95%CI 2.78-3.11). Fewer components of metabolic syndrome were associated with a lower risk of gout in both nonobese and obese patients.

Conclusion: When metabolic abnormalities were present, obesity induced a higher risk of gout. Different components of metabolic abnormalities had different effects on the risk of gout occurrence, and the number of metabolic abnormalities was closely related to the risk of gout occurrence. Follow-up and intervention methods targeting obesity and metabolic abnormalities should be considered for patients with gout.

« Previous Next »
Graphical Abstract

[1]
Dehlin, M.; Jacobsson, L.; Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol., 2020, 16(7), 380-390.
[http://dx.doi.org/10.1038/s41584-020-0441-1] [PMID: 32541923]
[2]
Dalbeth, N.; Gosling, A.L.; Gaffo, A.; Abhishek, A. Gout. Lancet., 2021, 397(10287), 1843-1855.
[http://dx.doi.org/10.1016/S0140-6736(21)00569-9] [PMID: 33798500]
[3]
Singh, J.A.; Gaffo, A. Gout epidemiology and comorbidities. Semin. Arthritis Rheum., 2020, 50(3), S11-S16.
[http://dx.doi.org/10.1016/j.semarthrit.2020.04.008] [PMID: 32620196]
[4]
Chen-Xu, M.; Yokose, C.; Rai, S.K.; Pillinger, M.H.; Choi, H.K. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: The national health and nutrition examination survey, 2007–2016. Arthritis Rheumatol., 2019, 71(6), 991-999.
[http://dx.doi.org/10.1002/art.40807] [PMID: 30618180]
[5]
Burke, B.T.; Köttgen, A.; Law, A.; Gwen Windham, B.; Segev, D.; Baer, A.N.; Coresh, J.; McAdams-DeMarco, M.A. Physical function, hyperuricemia, and gout in older adults. Arthritis Care Res., 2015, 67(12), 1730-1738.
[http://dx.doi.org/10.1002/acr.22648] [PMID: 26138016]
[6]
Rai, S.K.; Burns, L.C.; De Vera, M.A.; Haji, A.; Giustini, D.; Choi, H.K. The economic burden of gout: A systematic review. Semin. Arthritis Rheum., 2015, 45(1), 75-80.
[http://dx.doi.org/10.1016/j.semarthrit.2015.02.004] [PMID: 25912932]
[7]
Liu, S.C.; Xia, L.; Zhang, J.; Lu, X.H.; Hu, D.K.; Zhang, H.T.; Li, H.J. Gout and risk of myocardial infarction: A systematic review and meta-analysis of cohort studies. PLoS One., 2015, 10(7), e0134088.
[http://dx.doi.org/10.1371/journal.pone.0134088] [PMID: 26230580]
[8]
Roughley, M.J.; Belcher, J.; Mallen, C.D.; Roddy, E. Gout and risk of chronic kidney disease and nephrolithiasis: Meta-analysis of observational studies. Arthritis Res. Ther., 2015, 17(1), 90.
[http://dx.doi.org/10.1186/s13075-015-0610-9] [PMID: 25889144]
[9]
Fisher, M.C.; Rai, S.K.; Lu, N.; Zhang, Y.; Choi, H.K. The unclosing premature mortality gap in gout: A general population-based study. Ann. Rheum. Dis., 2017, 76(7), 1289-1294.
[http://dx.doi.org/10.1136/annrheumdis-2016-210588] [PMID: 28122760]
[10]
Mokdad, A.H.; Ford, E.S.; Bowman, B.A.; Dietz, W.H.; Vinicor, F.; Bales, V.S.; Marks, J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 2003, 289(1), 76-79.
[http://dx.doi.org/10.1001/jama.289.1.76] [PMID: 12503980]
[11]
Engin, A. The Definition And Prevalence Of Obesity And Metabolic Syndrome. Adv. Exp. Med. Biol., 2017, 960, 1-17.
[http://dx.doi.org/10.1007/978-3-319-48382-5_1] [PMID: 28585193]
[12]
Tung, Y.C.; Lee, M.Y.; Wang, Y.C.; Chang, C.J.; Tsai, W.C.; Lin, G.T.; Li, C.Y.; Lee, S.S.; Tu, H.P. Effect modification of hyperlipidemia and hypertension on the association between type 2 diabetes and gout. Prim. Care Diabetes, 2020, 14(6), 654-662.
[http://dx.doi.org/10.1016/j.pcd.2020.06.002] [PMID: 32593565]
[13]
Neeland, I.J.; Poirier, P.; Després, J.P. cardiovascular and metabolic heterogeneity of obesity. Circulation, 2018, 137(13), 1391-1406.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029617] [PMID: 29581366]
[14]
Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.T.; Loria, C.M.; Smith, S.C., Jr. Harmonizing The Metabolic Syndrome. Circulation, 2009, 120(16), 1640-1645.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644] [PMID: 19805654]
[15]
Evans, P.L.; Prior, J.A.; Belcher, J.; Mallen, C.D.; Hay, C.A.; Roddy, E. Obesity, hypertension and diuretic use as risk factors for incident gout: A systematic review and meta-analysis of cohort studies. Arthritis Res. Ther., 2018, 20(1), 136.
[http://dx.doi.org/10.1186/s13075-018-1612-1] [PMID: 29976236]
[16]
Maglio, C.; Peltonen, M.; Neovius, M.; Jacobson, P.; Jacobsson, L.; Rudin, A.; Carlsson, L.M.S. Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: A non-randomised, prospective, controlled intervention trial. Ann. Rheum. Dis., 2017, 76(4), 688-693.
[http://dx.doi.org/10.1136/annrheumdis-2016-209958] [PMID: 28076240]
[17]
Kuo, C.F.; Grainge, M.J.; Mallen, C.; Zhang, W.; Doherty, M. Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann. Rheum. Dis., 2016, 75(1), 210-217.
[http://dx.doi.org/10.1136/annrheumdis-2014-206410] [PMID: 25398375]
[18]
Zhu, Y.; Pandya, B.J.; Choi, H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am. J. Med., 2012, 125(7), 679-687.e1.
[http://dx.doi.org/10.1016/j.amjmed.2011.09.033] [PMID: 22626509]
[19]
Pan, A.; Teng, G.G.; Yuan, J.M.; Koh, W.P. Bidirectional Association Between Self-Reported Hypertension And Gout: The Singapore Chinese Health Study. PLoS One., 2015, 10(10), e0141749.
[http://dx.doi.org/10.1371/journal.pone.0141749] [PMID: 26510154]
[20]
Gao, B.; Zhou, J.; Ge, J.; Zhang, Y.; Chen, F.; Lau, W.B.; Wan, Y.; Zhang, N.; Xing, Y.; Wang, L.; Fu, J.; Li, X.; Jia, H.; Zhao, X.; Ji, Q. Association of maximum weight with hyperuricemia risk: A retrospective study of 21,414 Chinese people. PLoS One., 2012, 7(11), e51186.
[http://dx.doi.org/10.1371/journal.pone.0051186] [PMID: 23226486]
[21]
Mastrototaro, L.; Roden, M. Insulin resistance and insulin sensitizing agents. Metabolism., 2021, 125, 154892.
[http://dx.doi.org/10.1016/j.metabol.2021.154892] [PMID: 34563556]
[22]
McCormick, N.; O’Connor, M.J.; Yokose, C.; Merriman, T.R.; Mount, D.B.; Leong, A.; Choi, H.K. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization. Arthritis Rheumatol., 2021, 73(11), 2096-2104.
[http://dx.doi.org/10.1002/art.41779] [PMID: 33982892]
[23]
Yanai, H.; Adachi, H.; Hakoshima, M.; Katsuyama, H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int. J. Mol. Sci., 2021, 22(17), 9221.
[http://dx.doi.org/10.3390/ijms22179221] [PMID: 34502127]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy